EUCTR2006-006513-33-GB进行中（未招募）1 期
A double-blind, randomized, parallel group comparison of Nizoral® cream (F012), ketoconazole 2% cream (F126) and placebo (F000) in the treatment of interdigital Tinea Pedis. - Ketoconazole cream formulations in Tinea pedis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Male or female subjects aged 18 years or more.
- •2.Subjects must be co-operative, reliable and sufficiently competent to grade and record symptoms as requested.
- •3.Clinical diagnosis of uncomplicated interdigital Tinea pedis confirmed by KOH microscopy.
- •4.Female subjects must be, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; have a negative urine pregnancy test at screening.
- •5.Willing to adhere to the prohibitions and restrictions specified in this protocol.
- •6.Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Complicated Tinea pedis defined as: Confluent, diffuse moccasin type tinea pedis of the entire plantar surface, onychomycosis; other dermatomycosis requiring active treatment.
- •2.Subjects with a previous sensitivity to imidazole antifungal agents or to any ingredient of the study medication.
- •3.History of disallowed therapies: history of oral antifungal treatments within the previous 6 weeks; recent use (within two weeks of the study start) of topical antifungal agent; immunosuppressive or radiation therapy within the previous four weeks; recent use (within two weeks prior to screening) of other oral antibiotics, systemic corticosteroids or topical corticosteroids or antibiotics applied to the feet.
- •4.Recent history of drug or alcohol abuse, psychosis, or other condition making the subject unlikely to comply with the protocol.
- •5.Known HIV-positive (testing will not be performed).
- •6.Uncontrolled diabetes mellitus or peripheral vascular disease requiring active treatment.
- •7.Clinically relevant abnormal findings on clinical examination of the feet.
- •8.Any subject in whom skin scraping would be considered contraindicated.
- •9.Have received an experimental drug or used an experimental medical device within 30 days prior to the study or within five half-lives of the investigational drug, whichever is longer.
- •10.Is pregnant or breast-feeding.
- •11.Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究者
相似试验
已完成
不适用
Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean feverfamilial Mediterranean feverJPRN-UMIN000028010Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences23
尚未招募
3 期
A clinical trial of herbal products in the management of knee osteoarthritisCTRI/2023/07/054799Phytoveda Pvt. Ltd.
尚未招募
Unknown
Clinical study of nutritional formulations in the management of knee osteoarthritis.CTRI/2024/07/070163ife Synergy
已完成
不适用
A randomised, double-blind, parallel-group comparison of the efficacy and the safety of venlafaxine versus nortriptyline in the treatment of depressed elderly inpatientsDepressive disordersMental and Behavioural DisordersDepressionISRCTN23246262Altrecht GGZ (The Netherlands)81
招募中
1 期
A randomised, double blind, parallel group, comparative Phase I study to evaluate the safety and pharmacokinetics of a single intravenous dose of GB221 compared to Herceptin Registered Trademark (trastuzumab) in healthy volunteers.ACTRN12611001171909Genor Biopharma32